EBR/CYAD (EBR/CYAD)

Euronext Brussels: EBR/CYAD · EUR

€0.21

+0.00 (0.0%)· Recorded snapshot

Market cap	9.4M
Revenue (ttm)	7K
Net income (ttm)	3.3M
EPS (ttm)	€0.07
Shares out	44.8M
P/E (trailing)	3.1x
Volume	12,282
Beta	1.25

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 7K
Net income (ttm): 3.3M
EPS (ttm): €0.07
P/E (trailing): 3.1x
Market cap: 9.4M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E3.1

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All EBR/CYAD indicators

Market & fundamental data

Available fields

184

Groups with data

Currency

EUR

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	Belgium
Country code	BE
Earnings date	2027-09-24
Employees	5
Employees change	-14
Employees growth	-73.68%
Enterprise value	EUR 9.3M
Exchange	Euronext Brussels
Financial currency	EUR
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	2004
Industry	Biotechnology
Is primary listing	Yes
ISIN number	BE0974260896
Last earnings date	2026-09-23
Last refreshed	2026-10-28
Market cap	EUR 9.4M
Next earnings date	2027-09-24
Price	EUR 0.21
Price currency	EUR
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	ebr/CYAD
Website	https://celyad.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	32.76%
EV/Earnings	2.82x
EV/EBIT	9.97x
EV/EBITDA	10.51x
FCF / EV yield	-55.04%
FCF yield	-54.33%
Graham number	0.20841
Graham upside	1.17%
Industry P/E	28.77x
P/B ratio	7.48x
P/E ratio	3.05x
P/S ratio	1,342.86x
Price / tangible book value	7.56x
Price/EBITDA ratio	12.13x
Sector forward P/E	22.94x
Sector P/E	29.62x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	13,300%
EBITDA margin	11,071.43%
Gross margin	3,357.14%
Operating margin	13,300%
Pretax margin	47,071.43%
Profit margin	47,071.43%
Profit per employee	EUR 659,000
Profitable years	1
Revenue per employee	EUR 1,400
ROA	14.51%
ROA (5Y)	-25.95%
ROCE	66.74%
ROE (5Y)	-103.09%
SBC / revenue	1,271.43%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	7
EPS growth years	3
Net income growth quarters	2
Net income growth years	3
Revenue growth	-96.24%
Revenue growth 10Y	-16.6%
Revenue growth 3Y	-45.81%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	EUR -156,000
EBIT	EUR 931,000
EBITDA	EUR 775,000
EPS	EUR 0.07
FCF per share	EUR -0.11
Financing cash flow	EUR 1.4M
Free cash flow	EUR -5.1M
Free cash flow minus SBC	EUR -5.2M
Gross profit	EUR 235,000
Investing cash flow	EUR 3M
Net borrowing	EUR -53,000
Net cash flow	EUR -669,000
Net income	EUR 3.3M
Operating cash flow minus SBC	EUR -5.2M
Operating income	EUR 931,000
Revenue	EUR 7,000
Stock-based compensation	EUR 89,000

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-211.22
Book value per share	EUR 0.03
Debt / equity	0
Interest coverage	21.16
Long-term assets	EUR 1.5M
Long-term liabilities	EUR 139,000
Net cash (debt)	EUR 121,000
Net cash / market cap	1.29%
Net debt / EBITDA	-0.16
Net debt / equity	-0.1
Piotroski F-Score	4
Shareholders' equity	EUR 1.3M
Tangible book value	EUR 1.2M
Tangible book value per share	EUR 0.03
Total assets	EUR 2.3M
Total cash	EUR 121,000
Total debt	EUR 0
Total liabilities	EUR 1.1M
WACC	11.13%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0
Current assets	EUR 871,000
Current liabilities	EUR 930,000
Current ratio	0.94
Net working capital	EUR -180,000
Quick ratio	0.91
Working capital	EUR -59,000
Working capital turnover	-0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-15.71%
Shareholder yield	-15.71%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-98.58%
10Y return CAGR	-34.68%
10Y total return	-98.58%
150-day SMA	EUR 0.27
1D price change	0%
1M price change	-10.64%
1M total return	-10.64%
1Y price change	-0.94%
1Y return CAGR	-0.94%
1Y total return	-0.94%
20-day SMA	EUR 0.22
200-day SMA	EUR 0.27
3M price change	-27.34%
3M total return	-27.34%
3Y price change	-65.12%
3Y return CAGR	-29.6%
3Y total return	-65.12%
50-day SMA	EUR 0.24
50-day SMA vs 200-day SMA	50under200
52-week high	EUR 0.65
52-week high date	2026-02-17
52-week low	EUR 0.16
52-week low date	2025-12-30
5Y price change	-94.47%
5Y return CAGR	-43.97%
5Y total return	-94.47%
6M price change	-30.46%
6M total return	-30.46%
All-time high	EUR 70.95
All-time high date	2015-05-25
All-time low	EUR 0.16
All-time low date	2025-12-30
Average true range (ATR)	EUR 0.02
Average volume	9.4K
Beta (1Y)	1.61
Beta (2Y)	0.51
Beta (5Y)	1.25
Change from 52-week high	-67.69%
Change from 52-week low	31.25%
Change from all-time high	-99.7%
Change from all-time low	31.25%
Change from open	1.94%
Day's gap	-1.9%
Dollar volume	EUR 2,579
High price	EUR 0.21
Low price	EUR 0.21
Monthly RSI	37.25
Open price	EUR 0.21
Position in 52-week range	100%
Previous close	EUR 0.21
Price vs 150-day SMA	-21.29%
Price vs 20-day SMA	-2.6%
Price vs 200-day SMA	-23.19%
Price vs 50-day SMA	-12.02%
Relative volume	1.31
RSI	45.61
Sharpe ratio	0.47
Sharpe ratio (3Y)	0.2
Sharpe ratio (5Y)	-0.01
Sortino ratio	0.95
Sortino ratio (3Y)	0.48
Sortino ratio (5Y)	0.06
Volume	12.3K
Weekly RSI	39.02
YTD price change	23.53%
YTD total return	23.53%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	14.2M
Shares change (QoQ)	-12.42%
Shares change (YoY)	15.71%
Shares held by insiders	0.45%
Shares held by institutions	0.08%
Shares outstanding	44.8M

Deeper analysis on EBR/CYAD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this EBR/CYAD report

Is a complete EBR/CYAD research report available?

No complete published report is available for ebr/CYAD (EBR/CYAD) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

EBR/CYAD (EBR/CYAD)

Price

Financial snapshot

Fair-value bridge

Latest news · EBR/CYAD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All EBR/CYAD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on EBR/CYAD

Frequently asked questions